1st CFP MultiCardioNER (CLEF/BioASQ 2024): Clinical Named Entity Recognition adaptation shared task (multilingual & cardiology)
Martin Krallinger via Corpora <[email protected]> Mon, 15 Apr 2024 11:41:54 +0200
| Newsgroups | gmane.science.linguistics.corpora,gmane.org.w3c.semantic-web |
|---|---|
| Message-ID | <CAMx+MKES-6Uk6Sx6mbiwZ=3x3R8pGnE3XtUrVd1MBhR9bPoxoA@mail.gmail.com> |
--===============5213896791621759736==
Content-Type: multipart/alternative; boundary="00000000000035929806161f6f43"
--00000000000035929806161f6f43
Content-Type: text/plain; charset="UTF-8"
Content-Transfer-Encoding: quoted-printable
(Apologies for cross-posting)
*CFP MultiCardioNER (CLEF/BioASQ 2024): Clinical Named Entity Recognition
adaptation shared task (multilingual & cardiology)*
*https://temu.bsc.es/multicardioner/ <https://temu.bsc.es/multicardioner/>*
The MultiCardioNER track focuses on the adaptation of clinical NER systems
to specific high impact clinical application domains (cardiovascular
diseases, the leading cause of death globally) as well as to multiple
languages (English, Spanish and Italian), focusing on two clinical entity
types: diseases and medications.
*Key information:*
=C2=B7 *Web*: https://temu.bsc.es/multicardioner
=C2=B7 *Data*: https://zenodo.org/records/10948355
=C2=B7 *BioASQ** web*: http://bioasq.org/
=C2=B7 *Registration**:* https://temu.bsc.es/multicardioner/registrat=
ion/
*Motivation *The extraction of clinical variables from medical content is
key to enable efficient healthcare data analytics. Due to the highly
specialized medical language, with considerable variation depending on the
medical discipline, more specialized automatic semantic annotation
resources are needed, not only for English but also other languages.
This is particularly true for clinical content related to cardiovascular
diseases (CVDs), which represent the leading cause of death globally,
responsible for approximately 17.9 million deaths/year.
The MultiCardioNER task will focus on the automatic recognition of two key
clinical variables or concept types, namely diseases and medications in
cardiology clinical case documents with the following two aims:
=C2=B7 Adaptation of general clinical concept recognition systems to
cardiology case reports to assess and determine how well such systems can
be adapted to high impact clinical application domains / specialties
(cardiology disease NER - CardioDis subtrack: Spanish).
=C2=B7 Promote the comparative assessment and development of clinical
entity recognition systems for multiple languages (i.e., medication mention
detection) as well as adaptation to specific medical specialties (MultiDrug
subtrack: English, Spanish and Italian)
To enable the adaptation of general medical NER systems for diseases and
medications the MultiCardioNER task will rely on a training collection of
1000 general clinical case reports in Spanish annotated with diseases
(Spanish) and medications (English, Spanish and Italian).
Moreover, to be able to adapt such general medical NER approaches to
cardiology case reports a development set of 250 cardiology cases will be
released. The test set will consist of an additional test collection of 250
cardiology case reports.
The evaluation of systems for this task will use flat evaluation, mainly
micro-averaged Precision, Recall and F-measure (MiF).
Sub-tracks:
*Subtask 1 (CardioDis): *Spanish adaptation of disease recognition systems
to the cardiology domain
*Subtask 2 (MultiDrug): *Multilingual (Spanish, English and Italian)
adaptation of medication recognition systems to the cardiology domain
*Tentative schedule*
=C2=B7 MultiCardioNER Train+Dev Set Release April 9th, 2024
=C2=B7 MultiCardioNER Annotation Guidelines Release April =
17th,
2024
=C2=B7 MultiCardioNER Gazetteer Release April 17th, 2024
=C2=B7 MultiCardioNER Test Set Texts Release May 2nd, 2024
=C2=B7 Participant Test Predictions Deadline
=C2=B7 May 15th, 2024
=C2=B7 Participant Evaluation Result Release May 19th, =
2024
=C2=B7 Submission of Participant Papers Deadline May 31st, 2024
=C2=B7 Notification of Acceptance of Participant Papers Jun=
e
24th, 2024
=C2=B7 Submission of Camera-ready Participant Papers Deadline
July 8th, 2024
=C2=B7 BioASQ @ CLEF2024 September 9th-12th, 2024
*Publications & conference*
Following previous BioASQ/CLEF efforts, participating teams will be invited
to contribute a short systems description paper for the CLEF 2024
proceedings, and to give a short presentation of their approach at the
BioASQ workshop at the CLEF 2024 conference (September 09-12, 2024, in
Grenoble, France)
*The **MultiCardioNER Organizers & collaborators:*
- Salvador Lima-L=C3=B3pez, Barcelona Supercomputing Center (BSC), Spain
- Eul=C3=A0lia Farr=C3=A9-Maduell, Barcelona Supercomputing Center (BSC)=
, Spain
- Jan Rodr=C3=ADguez-Miret, Barcelona Supercomputing Center (BSC), Spain
- Martin Krallinger, Barcelona Supercomputing Center (BSC), Spain
- Anastasios Nentidis, National Center for Scientific Research
Demokritos, Greece
- Anastasia Krithara, National Center for Scientific Research
Demokritos, Greece
- Georgios Katsimpras, National Center for Scientific Research
Demokritos, Greece
- Livia Lilli, Fondazione Policlinico Universitario Agostino Gemelli
IRCCS, Italy
- Jacopo Lenkowicz, Fondazione Policlinico Universitario Agostino
Gemelli IRCCS, Italy
- Jonathan Kossoff, University College London Hospitals NHS Foundation
Trust, UK
- Giovanna Ceroni, University College London, UK
- Anoop Shah, University College London Hospitals NHS Foundation Trust,
UK
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D
Martin Krallinger, Dr.
Head of NLP for Biomedical Information Analysis Unit
Barcelona Supercomputing Center (BSC-CNS)
https://www.linkedin.com/in/martin-krallinger-85495920/
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D
--00000000000035929806161f6f43
Content-Type: text/html; charset="UTF-8"
Content-Transfer-Encoding: quoted-printable
<div dir=3D"ltr"><p class=3D"MsoNormal" style=3D"margin:0cm;font-size:12pt;=
font-family:Calibri,sans-serif"><span lang=3D"ES" style=3D"font-size:11pt;f=
ont-family:Arial,sans-serif;color:black">(</span><span style=3D"font-size:1=
1pt;font-family:Arial,sans-serif;color:black">Apologies for cross-posting)<=
/span><span style=3D"font-family:Arial,sans-serif"></span></p>
<p class=3D"MsoNormal" style=3D"margin:0cm;font-size:12pt;font-family:Calib=
ri,sans-serif"><span style=3D"font-family:Arial,sans-serif">=C2=A0</span></=
p>
<p class=3D"MsoNormal" style=3D"margin:0cm;font-size:12pt;font-family:Calib=
ri,sans-serif"><span style=3D"font-family:Arial,sans-serif">=C2=A0</span></=
p>
<p class=3D"MsoNormal" align=3D"center" style=3D"text-align:center;margin:0=
cm;font-size:12pt;font-family:Calibri,sans-serif"><b><span style=3D"font-si=
ze:10pt;color:black">CFP MultiCardioNER (CLEF/BioASQ 2024):
Clinical Named Entity Recognition adaptation shared task (multilingual &=
;
cardiology)</span></b></p>
<p class=3D"MsoNormal" style=3D"margin:0cm;font-size:12pt;font-family:Calib=
ri,sans-serif"><span style=3D"font-family:Arial,sans-serif">=C2=A0</span></=
p>
<p class=3D"MsoNormal" align=3D"center" style=3D"text-align:center;margin:0=
cm;font-size:12pt;font-family:Calibri,sans-serif"><u><span style=3D"font-si=
ze:10pt;color:rgb(17,85,204)"><a href=3D"https://temu.bsc.es/multicardioner=
/" style=3D"color:blue">https://temu.bsc.es/multicardioner/</a></span></u><=
span style=3D"font-family:Arial,sans-serif"></span></p>
<p class=3D"MsoNormal" align=3D"center" style=3D"text-align:center;margin:0=
cm;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"font-size:=
11pt;font-family:Arial,sans-serif;color:black">=C2=A0</span><span style=3D"=
font-family:Arial,sans-serif"></span></p>
<p class=3D"MsoNormal" style=3D"text-align:justify;margin:0cm;font-size:12p=
t;font-family:Calibri,sans-serif"><span style=3D"font-size:10pt;color:black=
">The </span><span lang=3D"EN-US" style=3D"font-size:10pt;color:black">Mult=
iCardioNER</span><span style=3D"font-size:10pt;color:black"> track focuses =
on the</span><span style=3D"font-size:10pt;color:black"> <span lang=3D"EN-U=
S">adaptation of clinical NER systems to specific high impact clinical
application domains (</span></span><span style=3D"font-size:10pt;color:blac=
k">cardiovascular
diseases</span><span lang=3D"EN-US" style=3D"font-size:10pt;color:black">,<=
/span><span lang=3D"EN-US" style=3D"font-size:10pt;color:black"> </span><sp=
an style=3D"font-size:10pt;color:black">the leading cause of death globally=
</span><span lang=3D"EN-US" style=3D"font-size:10pt;color:black">) as well =
as to
multiple languages (English, Spanish and Italian), focusing on two clinical
entity types: diseases and medications.</span><span style=3D"font-size:10pt=
;color:black"></span></p>
<p class=3D"MsoNormal" style=3D"text-align:justify;margin:0cm;font-size:12p=
t;font-family:Calibri,sans-serif"><span style=3D"font-family:Arial,sans-ser=
if">=C2=A0</span></p>
<p class=3D"MsoNormal" style=3D"margin:0cm;font-size:12pt;font-family:Calib=
ri,sans-serif"><b><span style=3D"font-size:10pt;color:black">Key
information:</span></b><span style=3D"font-family:Arial,sans-serif"></span>=
</p>
<p class=3D"MsoNormal" style=3D"margin:0cm 0cm 0cm 51.8pt;vertical-align:ba=
seline;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"font-s=
ize:10pt;font-family:Symbol;color:black">=C2=B7<span style=3D"font-variant-=
numeric:normal;font-variant-east-asian:normal;font-variant-alternates:norma=
l;font-kerning:auto;font-feature-settings:normal;font-stretch:normal;font-s=
ize:7pt;line-height:normal;font-family:"Times New Roman"">=C2=A0=
=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0
</span></span><b><span style=3D"font-size:10pt;color:black">Web</span></b><=
span style=3D"font-size:10pt;color:black">: <a href=3D"https://temu.bsc.es/=
multicardioner">https://temu.bsc.es/multicardioner</a></span><span style=3D=
"font-size:10pt;font-family:Arial,sans-serif;color:black"></span></p>
<p class=3D"MsoNormal" style=3D"margin:0cm 0cm 0cm 51.8pt;vertical-align:ba=
seline;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"font-s=
ize:10pt;font-family:Symbol;color:black">=C2=B7<span style=3D"font-variant-=
numeric:normal;font-variant-east-asian:normal;font-variant-alternates:norma=
l;font-kerning:auto;font-feature-settings:normal;font-stretch:normal;font-s=
ize:7pt;line-height:normal;font-family:"Times New Roman"">=C2=A0=
=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0
</span></span><b><span style=3D"font-size:10pt;color:black">Data</span></b>=
<span style=3D"font-size:10pt;color:black">:</span>=C2=A0<span style=3D"fon=
t-size:10pt;color:rgb(17,85,204)"><a href=3D"https://zenodo.org/records/109=
48355">https://zenodo.org/records/10948355</a></span><span style=3D"font-si=
ze:10pt;font-family:Arial,sans-serif;color:black"></span></p>
<p class=3D"MsoNormal" style=3D"margin:0cm 0cm 0cm 51.8pt;vertical-align:ba=
seline;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"font-s=
ize:10pt;font-family:Symbol;color:black">=C2=B7<span style=3D"font-variant-=
numeric:normal;font-variant-east-asian:normal;font-variant-alternates:norma=
l;font-kerning:auto;font-feature-settings:normal;font-stretch:normal;font-s=
ize:7pt;line-height:normal;font-family:"Times New Roman"">=C2=A0=
=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0
</span></span><b><span lang=3D"EN-US" style=3D"font-size:10pt;color:black">=
BioASQ</span></b><b><span style=3D"font-size:10pt;color:black"> web</span><=
/b><span style=3D"font-size:10pt;color:black">: <a href=3D"http://bioasq.or=
g/">http://bioasq.org/</a></span></p>
<p class=3D"MsoNormal" style=3D"margin:0cm 0cm 0cm 51.8pt;vertical-align:ba=
seline;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"font-s=
ize:10pt;font-family:Symbol;color:black">=C2=B7<span style=3D"font-variant-=
numeric:normal;font-variant-east-asian:normal;font-variant-alternates:norma=
l;font-kerning:auto;font-feature-settings:normal;font-stretch:normal;font-s=
ize:7pt;line-height:normal;font-family:"Times New Roman"">=C2=A0=
=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0
</span></span><b><span style=3D"font-size:10pt;color:black">Registration</s=
pan></b><b><span lang=3D"EN-US" style=3D"font-size:10pt;color:black">:</spa=
n></b><b><span lang=3D"EN-US" style=3D"font-size:10pt;color:black"> </span>=
</b><span style=3D"font-size:10pt;color:black"><a href=3D"https://temu.bsc.=
es/multicardioner/registration/">https://temu.bsc.es/multicardioner/registr=
ation/</a></span></p>
<p class=3D"MsoNormal" style=3D"margin:10pt 0cm 0cm;text-align:justify;font=
-size:12pt;font-family:Calibri,sans-serif"><span style=3D"font-size:10pt;co=
lor:rgb(17,85,204)"><br>
</span><b><span style=3D"font-size:10pt;color:black">Motivation<br>
</span></b><span style=3D"font-size:10pt;color:black">The
extraction of clinical variables from medical content is key to enable effi=
cient healthcare data analytics. Due to the highly specialized medical lang=
uage, with
considerable variation depending on the medical </span><span lang=3D"EN-US"=
style=3D"font-size:10pt;color:black">discipline</span><span style=3D"font-=
size:10pt;color:black">, more specialized automatic semantic
annotation resources are needed, not only for English but also other langua=
ges.
</span></p>
<p class=3D"MsoNormal" style=3D"margin:10pt 0cm 0cm;text-align:justify;font=
-size:12pt;font-family:Calibri,sans-serif"><span style=3D"font-size:10pt;co=
lor:black">This is particularly true for clinical
content related to cardiovascular diseases (CVDs), which represent the
leading cause of death globally, responsible for approximately 17.9 million
deaths/year.</span></p>
<p class=3D"MsoNormal" style=3D"margin:10pt 0cm 0cm;text-align:justify;font=
-size:12pt;font-family:Calibri,sans-serif"><span lang=3D"EN-US" style=3D"fo=
nt-size:10pt;color:black">The</span><span lang=3D"EN-US" style=3D"font-size=
:10pt;color:black"> </span><span style=3D"font-size:10pt;color:black">Multi=
CardioNER </span><span lang=3D"EN-US" style=3D"font-size:10pt;color:black">=
task </span><span style=3D"font-size:10pt;color:black">will focus on the au=
tomatic recognition
of two key clinical variables or concept types, namely diseases and medicat=
ions</span><span style=3D"font-size:10pt;color:black"> </span><span style=
=3D"font-size:10pt;color:black">in cardiology clinical case documents
with the following two aims:</span></p>
<p class=3D"gmail-MsoListParagraphCxSpFirst" style=3D"margin:10pt 0cm 0cm 3=
6pt;text-align:justify;font-size:12pt;font-family:Calibri,sans-serif"><span=
style=3D"font-size:10pt;font-family:Symbol;color:black">=C2=B7<span style=
=3D"font-variant-numeric:normal;font-variant-east-asian:normal;font-variant=
-alternates:normal;font-kerning:auto;font-feature-settings:normal;font-stre=
tch:normal;font-size:7pt;line-height:normal;font-family:"Times New Rom=
an"">=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0
</span></span><span style=3D"font-size:10pt;color:black">Adaptation
of general clinical concept recognition systems to cardiology case reports =
to
assess and determine how well such systems can be adapted to high impact
clinical application domains / specialties (cardiology disease NER - Cardio=
Dis
subtrack: Spanish).</span></p>
<p class=3D"gmail-MsoListParagraphCxSpLast" style=3D"margin:10pt 0cm 0cm 36=
pt;text-align:justify;font-size:12pt;font-family:Calibri,sans-serif"><span =
style=3D"font-size:10pt;font-family:Symbol;color:black">=C2=B7<span style=
=3D"font-variant-numeric:normal;font-variant-east-asian:normal;font-variant=
-alternates:normal;font-kerning:auto;font-feature-settings:normal;font-stre=
tch:normal;font-size:7pt;line-height:normal;font-family:"Times New Rom=
an"">=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0
</span></span><span style=3D"font-size:10pt;color:black">Promote
the comparative assessment and development of clinical entity recognition
systems for multiple languages (i.e., medication mention detection) as well=
as
adaptation to specific medical specialties (MultiDrug subtrack: English,
Spanish and Italian)</span></p>
<p class=3D"MsoNormal" style=3D"margin:10pt 0cm 0cm;text-align:justify;font=
-size:12pt;font-family:Calibri,sans-serif"><span style=3D"font-size:10pt;co=
lor:black">To enable the adaptation of general
medical NER systems for diseases and medications the MultiCardioNER task wi=
ll
rely on a training collection of 1000 general clinical case reports in Span=
ish
annotated with diseases (Spanish) and medications (English, Spanish and
Italian).</span></p>
<p class=3D"MsoNormal" style=3D"margin:10pt 0cm 0cm;text-align:justify;font=
-size:12pt;font-family:Calibri,sans-serif"><span style=3D"font-size:10pt;co=
lor:black">Moreover, </span><span lang=3D"EN-US" style=3D"font-size:10pt;co=
lor:black">t</span><span style=3D"font-size:10pt;color:black">o be able to =
adapt such general medical
NER approaches to cardiology case reports a development set of 250 cardiolo=
gy
cases will be released.</span><span style=3D"font-size:10pt;color:black"> <=
/span><span style=3D"font-size:10pt;color:black">The test
set will consist of an additional test collection of 250 cardiology case
reports</span><span lang=3D"EN-US" style=3D"font-size:10pt;color:black">.</=
span></p>
<p class=3D"MsoNormal" style=3D"margin:10pt 0cm 0cm;text-align:justify;font=
-size:12pt;font-family:Calibri,sans-serif"><span style=3D"font-size:10pt;co=
lor:black">The evaluation of systems for this task
will use flat evaluation, mainly micro-averaged Precision, Recall and F-mea=
sure
(MiF).</span></p>
<p class=3D"MsoNormal" style=3D"margin:0cm 0cm 12pt;font-size:12pt;font-fam=
ily:Calibri,sans-serif"><span style=3D"font-family:Arial,sans-serif">=C2=A0=
</span></p>
<p class=3D"MsoNormal" style=3D"margin:0cm 0cm 12pt;font-size:12pt;font-fam=
ily:Calibri,sans-serif"><span lang=3D"ES" style=3D"font-family:Arial,sans-s=
erif">S</span><span style=3D"font-size:10pt;color:black">ub-tracks:</span><=
span style=3D"font-family:Arial,sans-serif"></span></p>
<p class=3D"MsoNormal" style=3D"margin:0cm 0cm 0cm 36pt;font-size:12pt;font=
-family:Calibri,sans-serif"><b><span style=3D"font-size:10pt;color:black">S=
ubtask 1 (CardioDis): </span></b><span style=3D"font-size:10pt;color:black"=
>Spanish adaptation of disease
recognition systems to the cardiology domain<b></b></span></p>
<p class=3D"MsoNormal" style=3D"margin:0cm 0cm 0cm 36pt;font-size:12pt;font=
-family:Calibri,sans-serif"><b><span style=3D"font-size:10pt;color:black">=
=C2=A0</span></b></p>
<p class=3D"MsoNormal" style=3D"margin:0cm 0cm 0cm 36pt;font-size:12pt;font=
-family:Calibri,sans-serif"><b><span style=3D"font-size:10pt;color:black">S=
ubtask 2 (MultiDrug): </span></b><span style=3D"font-size:10pt;color:black"=
>Multilingual (Spanish, English and
Italian) adaptation of medication recognition systems to the cardiology dom=
ain<br><b><br></b></span></p><p class=3D"MsoNormal" style=3D"margin:0cm 0cm=
0cm 36pt;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"fon=
t-size:10pt;color:black"><b><br></b></span></p><p class=3D"MsoNormal" style=
=3D"margin:0cm 0cm 0cm 36pt;font-size:12pt;font-family:Calibri,sans-serif">=
<span style=3D"font-size:10pt;color:black"><b>Tentative schedule</b></span>=
<span style=3D"font-family:Arial,sans-serif"></span></p>
<p class=3D"gmail-MsoListParagraphCxSpFirst" style=3D"margin:0cm 0cm 0cm 36=
pt;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"font-size:=
10pt;font-family:Symbol;color:black">=C2=B7<span style=3D"font-variant-nume=
ric:normal;font-variant-east-asian:normal;font-variant-alternates:normal;fo=
nt-kerning:auto;font-feature-settings:normal;font-stretch:normal;font-size:=
7pt;line-height:normal;font-family:"Times New Roman"">=C2=A0=C2=
=A0=C2=A0=C2=A0=C2=A0=C2=A0
</span></span><span style=3D"font-size:10pt;color:black">MultiCardioNER
Train+Dev Set Release=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=
=C2=A0 April 9th,
2024</span></p>
<p class=3D"gmail-MsoListParagraphCxSpMiddle" style=3D"margin:0cm 0cm 0cm 3=
6pt;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"font-size=
:10pt;font-family:Symbol;color:black">=C2=B7<span style=3D"font-variant-num=
eric:normal;font-variant-east-asian:normal;font-variant-alternates:normal;f=
ont-kerning:auto;font-feature-settings:normal;font-stretch:normal;font-size=
:7pt;line-height:normal;font-family:"Times New Roman"">=C2=A0=C2=
=A0=C2=A0=C2=A0=C2=A0=C2=A0
</span></span><span style=3D"font-size:10pt;color:black">MultiCardioNER
Annotation Guidelines Release=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=
=A0=C2=A0=C2=A0=C2=A0 April
17th, 2024</span></p>
<p class=3D"gmail-MsoListParagraphCxSpMiddle" style=3D"margin:0cm 0cm 0cm 3=
6pt;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"font-size=
:10pt;font-family:Symbol;color:black">=C2=B7<span style=3D"font-variant-num=
eric:normal;font-variant-east-asian:normal;font-variant-alternates:normal;f=
ont-kerning:auto;font-feature-settings:normal;font-stretch:normal;font-size=
:7pt;line-height:normal;font-family:"Times New Roman"">=C2=A0=C2=
=A0=C2=A0=C2=A0=C2=A0=C2=A0
</span></span><span style=3D"font-size:10pt;color:black">MultiCardioNER
Gazetteer Release=C2=A0 April 17th, 2024</span></p>
<p class=3D"gmail-MsoListParagraphCxSpMiddle" style=3D"margin:0cm 0cm 0cm 3=
6pt;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"font-size=
:10pt;font-family:Symbol;color:black">=C2=B7<span style=3D"font-variant-num=
eric:normal;font-variant-east-asian:normal;font-variant-alternates:normal;f=
ont-kerning:auto;font-feature-settings:normal;font-stretch:normal;font-size=
:7pt;line-height:normal;font-family:"Times New Roman"">=C2=A0=C2=
=A0=C2=A0=C2=A0=C2=A0=C2=A0
</span></span><span style=3D"font-size:10pt;color:black">MultiCardioNER
Test Set Texts Release=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=
=A0=C2=A0=C2=A0 May 2nd,
2024</span></p>
<p class=3D"gmail-MsoListParagraphCxSpMiddle" style=3D"margin:0cm 0cm 0cm 3=
6pt;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"font-size=
:10pt;font-family:Symbol;color:black">=C2=B7<span style=3D"font-variant-num=
eric:normal;font-variant-east-asian:normal;font-variant-alternates:normal;f=
ont-kerning:auto;font-feature-settings:normal;font-stretch:normal;font-size=
:7pt;line-height:normal;font-family:"Times New Roman"">=C2=A0=C2=
=A0=C2=A0=C2=A0=C2=A0=C2=A0
</span></span><span style=3D"font-size:10pt;color:black">Participant
Test Predictions Deadline</span></p>
<p class=3D"gmail-MsoListParagraphCxSpMiddle" style=3D"margin:0cm 0cm 0cm 3=
6pt;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"font-size=
:10pt;font-family:Symbol;color:black">=C2=B7<span style=3D"font-variant-num=
eric:normal;font-variant-east-asian:normal;font-variant-alternates:normal;f=
ont-kerning:auto;font-feature-settings:normal;font-stretch:normal;font-size=
:7pt;line-height:normal;font-family:"Times New Roman"">=C2=A0=C2=
=A0=C2=A0=C2=A0=C2=A0=C2=A0
</span></span><span style=3D"font-size:10pt;color:black">May 15th,
2024</span></p>
<p class=3D"gmail-MsoListParagraphCxSpMiddle" style=3D"margin:0cm 0cm 0cm 3=
6pt;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"font-size=
:10pt;font-family:Symbol;color:black">=C2=B7<span style=3D"font-variant-num=
eric:normal;font-variant-east-asian:normal;font-variant-alternates:normal;f=
ont-kerning:auto;font-feature-settings:normal;font-stretch:normal;font-size=
:7pt;line-height:normal;font-family:"Times New Roman"">=C2=A0=C2=
=A0=C2=A0=C2=A0=C2=A0=C2=A0
</span></span><span style=3D"font-size:10pt;color:black">Participant
Evaluation Result Release=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=
=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0 May
19th, 2024</span></p>
<p class=3D"gmail-MsoListParagraphCxSpMiddle" style=3D"margin:0cm 0cm 0cm 3=
6pt;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"font-size=
:10pt;font-family:Symbol;color:black">=C2=B7<span style=3D"font-variant-num=
eric:normal;font-variant-east-asian:normal;font-variant-alternates:normal;f=
ont-kerning:auto;font-feature-settings:normal;font-stretch:normal;font-size=
:7pt;line-height:normal;font-family:"Times New Roman"">=C2=A0=C2=
=A0=C2=A0=C2=A0=C2=A0=C2=A0
</span></span><span style=3D"font-size:10pt;color:black">Submission
of Participant Papers Deadline=C2=A0=C2=A0=C2=A0=C2=A0 May
31st, 2024</span></p>
<p class=3D"gmail-MsoListParagraphCxSpMiddle" style=3D"margin:0cm 0cm 0cm 3=
6pt;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"font-size=
:10pt;font-family:Symbol;color:black">=C2=B7<span style=3D"font-variant-num=
eric:normal;font-variant-east-asian:normal;font-variant-alternates:normal;f=
ont-kerning:auto;font-feature-settings:normal;font-stretch:normal;font-size=
:7pt;line-height:normal;font-family:"Times New Roman"">=C2=A0=C2=
=A0=C2=A0=C2=A0=C2=A0=C2=A0
</span></span><span style=3D"font-size:10pt;color:black">Notification
of Acceptance of Participant Papers=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=
=A0=C2=A0=C2=A0=C2=A0 June
24th, 2024</span></p>
<p class=3D"gmail-MsoListParagraphCxSpMiddle" style=3D"margin:0cm 0cm 0cm 3=
6pt;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"font-size=
:10pt;font-family:Symbol;color:black">=C2=B7<span style=3D"font-variant-num=
eric:normal;font-variant-east-asian:normal;font-variant-alternates:normal;f=
ont-kerning:auto;font-feature-settings:normal;font-stretch:normal;font-size=
:7pt;line-height:normal;font-family:"Times New Roman"">=C2=A0=C2=
=A0=C2=A0=C2=A0=C2=A0=C2=A0
</span></span><span style=3D"font-size:10pt;color:black">Submission
of Camera-ready Participant Papers Deadline=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=
=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0 July
8th, 2024</span></p>
<p class=3D"gmail-MsoListParagraphCxSpLast" style=3D"margin:0cm 0cm 0cm 36p=
t;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"font-family=
:Symbol">=C2=B7<span style=3D"font-variant-numeric:normal;font-variant-east=
-asian:normal;font-variant-alternates:normal;font-kerning:auto;font-feature=
-settings:normal;font-stretch:normal;font-size:7pt;line-height:normal;font-=
family:"Times New Roman"">=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0 </span><=
/span><span style=3D"font-size:10pt;color:black">BioASQ @ CLEF2024=C2=A0=C2=
=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0 September 9=
th-12th, 2024<br>
<br>
<br>
</span><span style=3D"font-family:Arial,sans-serif"></span></p>
<p style=3D"margin:0cm;background-image:initial;background-position:initial=
;background-size:initial;background-repeat:initial;background-origin:initia=
l;background-clip:initial;font-size:12pt;font-family:"Times New Roman&=
quot;,serif"><b><span style=3D"font-size:10pt;font-family:Arial,sans-serif"=
>Publications & conference</span></b><span style=3D"font-size:10pt;font=
-family:Arial,sans-serif"></span></p>
<p style=3D"margin:0cm;text-align:justify;background-image:initial;backgrou=
nd-position:initial;background-size:initial;background-repeat:initial;backg=
round-origin:initial;background-clip:initial;font-size:12pt;font-family:&qu=
ot;Times New Roman",serif"><span style=3D"font-variant-numeric:normal;=
font-variant-east-asian:normal;font-variant-alternates:normal"><span style=
=3D"font-size:10pt;font-family:Arial,sans-serif">Following previous BioASQ/=
CLEF efforts,
participating teams will be invited to contribute a short systems descripti=
on
paper for the CLEF 202</span><span lang=3D"EN-US" style=3D"font-size:10pt;f=
ont-family:Arial,sans-serif">4</span><span style=3D"font-size:10pt;font-fam=
ily:Arial,sans-serif"> proceedings, and to
give a short presentation of their approach at the BioASQ workshop at the C=
LEF
202</span><span lang=3D"EN-US" style=3D"font-size:10pt;font-family:Arial,sa=
ns-serif">4</span><span style=3D"font-size:10pt;font-family:Arial,sans-seri=
f"> conference (September 09-12, 2024, in Grenoble</span><span lang=3D"EN-U=
S" style=3D"font-size:10pt;font-family:Arial,sans-serif">, </span><span sty=
le=3D"font-size:10pt;font-family:Arial,sans-serif">France)</span></span></p=
>
<p class=3D"MsoNormal" style=3D"margin:0cm;font-size:12pt;font-family:Calib=
ri,sans-serif"><span style=3D"font-size:10pt;color:black"><br>
<br>
</span><span style=3D"font-family:Arial,sans-serif"></span></p>
<p class=3D"MsoNormal" style=3D"margin:0cm;font-size:12pt;font-family:Calib=
ri,sans-serif"><span style=3D"font-family:Arial,sans-serif">=C2=A0</span></=
p>
<p class=3D"MsoNormal" style=3D"margin:0cm;font-size:12pt;font-family:Calib=
ri,sans-serif"><span style=3D"font-size:10pt;color:black"><br>
</span><b><span style=3D"font-size:10pt;color:black">The </span></b><b><spa=
n lang=3D"EN-GB" style=3D"font-size:10pt;color:black">MultiCardioNER
Organizers & collaborators:</span></b><b><span lang=3D"ES" style=3D"fon=
t-size:10pt;color:black"></span></b></p>
<p class=3D"MsoNormal" style=3D"margin:0cm;font-size:12pt;font-family:Calib=
ri,sans-serif"><b><span lang=3D"ES" style=3D"font-size:10pt;color:black">=
=C2=A0</span></b></p>
<ul style=3D"margin-top:0cm;margin-bottom:0cm" type=3D"disc">
<li class=3D"MsoNormal" style=3D"color:black;margin:0cm;font-size:12pt;fon=
t-family:Calibri,sans-serif"><span style=3D"font-size:10pt">Salvador Lima-L=
=C3=B3pez, Barcelona Supercomputing
Center (BSC), Spain</span></li>
<li class=3D"MsoNormal" style=3D"color:black;margin:0cm;font-size:12pt;fon=
t-family:Calibri,sans-serif"><span style=3D"font-size:10pt">Eul=C3=A0lia Fa=
rr=C3=A9-Maduell, Barcelona
Supercomputing Center (BSC), Spain</span></li>
<li class=3D"MsoNormal" style=3D"color:black;margin:0cm;font-size:12pt;fon=
t-family:Calibri,sans-serif"><span style=3D"font-size:10pt">Jan Rodr=C3=ADg=
uez-Miret, Barcelona Supercomputing
Center (BSC), Spain</span></li>
<li class=3D"MsoNormal" style=3D"color:black;margin:0cm;font-size:12pt;fon=
t-family:Calibri,sans-serif"><span style=3D"font-size:10pt">Martin Kralling=
er, Barcelona Supercomputing
Center (BSC), Spain</span></li>
</ul>
<ul style=3D"margin-top:0cm;margin-bottom:0cm" type=3D"disc">
<li class=3D"MsoNormal" style=3D"color:black;margin:0cm;font-size:12pt;fon=
t-family:Calibri,sans-serif"><span style=3D"font-size:10pt">Anastasios Nent=
idis, National Center for
Scientific Research Demokritos, Greece</span></li>
<li class=3D"MsoNormal" style=3D"color:black;margin:0cm;font-size:12pt;fon=
t-family:Calibri,sans-serif"><span style=3D"font-size:10pt">Anastasia Krith=
ara, National Center for
Scientific Research Demokritos, Greece</span></li>
<li class=3D"MsoNormal" style=3D"color:black;margin:0cm;font-size:12pt;fon=
t-family:Calibri,sans-serif"><span style=3D"font-size:10pt">Georgios Katsim=
pras, National Center for
Scientific Research Demokritos, Greece</span></li>
</ul>
<ul style=3D"margin-top:0cm;margin-bottom:0cm" type=3D"disc">
<li class=3D"MsoNormal" style=3D"color:black;margin:0cm;font-size:12pt;fon=
t-family:Calibri,sans-serif"><span style=3D"font-size:10pt">Livia Lilli, Fo=
ndazione Policlinico
Universitario Agostino Gemelli IRCCS, Italy</span></li>
<li class=3D"MsoNormal" style=3D"color:black;margin:0cm;font-size:12pt;fon=
t-family:Calibri,sans-serif"><span style=3D"font-size:10pt">Jacopo Lenkowic=
z, Fondazione Policlinico
Universitario Agostino Gemelli IRCCS, Italy</span></li>
<li class=3D"MsoNormal" style=3D"color:black;margin:0cm;font-size:12pt;fon=
t-family:Calibri,sans-serif"><span style=3D"font-size:10pt">Jonathan Kossof=
f, University College London
Hospitals NHS Foundation Trust, UK</span></li>
<li class=3D"MsoNormal" style=3D"color:black;margin:0cm;font-size:12pt;fon=
t-family:Calibri,sans-serif"><span style=3D"font-size:10pt">Giovanna Ceroni=
, University College London, UK</span></li>
<li class=3D"MsoNormal" style=3D"color:black;margin:0cm;font-size:12pt;fon=
t-family:Calibri,sans-serif"><span style=3D"font-size:10pt">Anoop=C2=A0Shah=
, University College London
Hospitals NHS Foundation Trust, UK</span></li>
</ul>
<p class=3D"MsoNormal" style=3D"margin:0cm;font-size:12pt;font-family:Calib=
ri,sans-serif"><span style=3D"font-family:Arial,sans-serif"><br><br>
</span></p>
<p class=3D"MsoNormal" style=3D"margin:0cm;font-size:12pt;font-family:Calib=
ri,sans-serif"><span style=3D"font-family:Arial,sans-serif">=C2=A0</span></=
p>
<div>=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D<br>Martin Krallinger, Dr.<=
br><span style=3D"font-family:arial,helvetica,sans-serif">Head of NLP for B=
iomedical Information Analysis Unit<br></span><span style=3D"font-family:ar=
ial,helvetica,sans-serif">Barcelona Supercomputing Center (BSC-CNS)</span><=
/div><div><font face=3D"arial, helvetica, sans-serif"><a href=3D"https://ww=
w.linkedin.com/in/martin-krallinger-85495920/" target=3D"_blank">https://ww=
w.linkedin.com/in/martin-krallinger-85495920/</a><br></font>=C2=A0=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D</div>
<p class=3D"MsoNormal" style=3D"margin:0cm;font-size:12pt;font-family:Calib=
ri,sans-serif">=C2=A0</p></div>
--00000000000035929806161f6f43--
--===============5213896791621759736==
Content-Type: text/plain; charset="us-ascii"
MIME-Version: 1.0
Content-Transfer-Encoding: 7bit
Content-Disposition: inline
_______________________________________________
Corpora mailing list -- [email protected]
https://list.elra.info/mailman3/postorius/lists/corpora.list.elra.info/
To unsubscribe send an email to [email protected]
--===============5213896791621759736==--